Skip to main content

Hydrochlorothiazide / moexipril Pregnancy and Breastfeeding Warnings

Hydrochlorothiazide / moexipril is also known as: Uniretic

Hydrochlorothiazide / moexipril Pregnancy Warnings

This drug should not be used during pregnancy unless there are no alternatives and the benefit outweighs the risk to the fetus.

US FDA pregnancy category: D

Comments: Adequate methods of contraception should be encouraged.

Animal studies have failed to reveal evidence of teratogenicity. In humans, use of drugs that act on the renin angiotensin system (RAS) during the second and third trimesters increases fetal and neonatal morbidity and death. There are no controlled data in human pregnancy.

US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Hydrochlorothiazide / moexipril Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Yes (hydrochlorothiazide); Unknown (moexipril)
Excreted into animal milk: Data not available (moexipril)

See references

References for pregnancy information

  1. Product Information. Uniretic (hydrochlorothiazide-moexipril). Schwarz Pharma. 2001.

References for breastfeeding information

  1. Product Information. Uniretic (hydrochlorothiazide-moexipril). Schwarz Pharma. 2001.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.